Shen John T, Falanga Vincent
Department of Dermatology, Roger Williams Medical Center, Providence, Rhode Island 02908, USA.
J Cutan Med Surg. 2003 May-Jun;7(3):217-24. doi: 10.1007/s10227-002-0106-5.
Apligraf is a bioengineered skin product composed of neonatal fibroblasts and keratinocytes. The FDA has approved Apligraf for the treatment of chronic venous ulcers and diabetic ulcers.
We review the development of bioengineered skin, examine the cellular activities of various growth factors that may facilitate wound healing, and discuss the results of clinical trials with a particular construct, Apligraf, as proof of principle.
Bioengineered skin acts as a "smart" delivery system for growth factors and other stimulatory substances. Not only does it present a novel treatment for chronic and diabetic ulcers, but it could also be considered for application to other types of acute wounds.
Apligraf是一种由新生儿成纤维细胞和角质形成细胞组成的生物工程皮肤产品。美国食品药品监督管理局（FDA）已批准Apligraf用于治疗慢性静脉溃疡和糖尿病溃疡。
我们回顾生物工程皮肤的发展，研究各种可能促进伤口愈合的生长因子的细胞活性，并讨论以特定构建物Apligraf作为原理验证的临床试验结果。
生物工程皮肤作为生长因子和其他刺激物质的“智能”递送系统。它不仅为慢性和糖尿病溃疡提供了一种新的治疗方法，还可考虑应用于其他类型的急性伤口。
